Diagnosis and management of pergolide‐induced fibrosis
- 19 May 2004
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 19 (6) , 699-704
Abstract
We report on 2 patients treated with pergolide, 1 of whom developed pleural fibrosis and the other retroperitoneal fibrosis. In both cases, an extensive diagnostic evaluation and surgical intervention were required to reach a diagnosis. Based on our experience with these patients and a review of cases of pergolide‐induced fibrosis in the English‐language literature, we propose guidelines for the diagnosis and management of this rare complication. © 2004 Movement Disorder SocietyKeywords
This publication has 17 references indexed in Scilit:
- Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonistsMovement Disorders, 2004
- Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulationJournal of Allergy and Clinical Immunology, 2003
- Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolideNeurology, 2003
- The US Food and Drug Administration's Registry of Patients With Pergolide-Associated Valvular Heart DiseaseMayo Clinic Proceedings, 2003
- Valvular Heart Disease in Patients Taking PergolideMayo Clinic Proceedings, 2002
- Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolidePostgraduate Medical Journal, 2002
- Drugs and the PleuraChest, 1999
- Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson’s diseaseBritish Journal of Urology, 1998
- Retroperitoneal Fibrosis in a Patient with Parkinsonʼs Disease Treated with PergolideClinical Neuropharmacology, 1995
- Pleuropulmonary disease associated with dopamine agonist therapyAnnals of Neurology, 1991